SARS-CoV-2 infection: Available data on 15th April 2021

Damien Basille (1, 2) , Claire Andrejak (1, 2)

1 CHU Amiens-Picardie
2 AGIR - Agents infectieux, résistance et chimiothérapie - UR UPJV 4294

Introduction. - Since January 2020, when the first cases of SARS-CoV-2 infection were diagnosed in France, pulmonologists have been at the heart of the crisis and should be responsible for the management of acute COVID-19 (and any possible sequelae) Background. - Many drugs have been evaluated or are currently under evaluation as possible specific treatment for SARS-CoV-2. Nevertheless, as of April 15, 2021, the only recommended treatment in current practice is the ``standard of care'', i.e. the symptomatic management of infection with SARS-CoV-2. This review presents the state of knowledge on COVID-19 in the acute phase (virological, immunological, epidemiological and therapeutic data) available on 15th April, 2021. Outlook. - A large number of clinical trials are currently ongoing. It is important to propose to patients the opportunity to participate in clinical trials and to structure the research in order to complete the studies. Conclusion. - Current management is based on oxygen therapy, thromboprophylaxis and in some cases corticosteroids. No antiviral therapy is currently recommended. These data are constantly evolving. (C) 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Domaines: Sciences du Vivant [q-bio]

Damien Basille, Claire Andrejak. SARS-CoV-2 infection: Available data on 15th April 2021. Revue des Maladies Respiratoires, 2021, 38 (6), pp.616-625. ⟨10.1016/j.rmr.2021.04.014⟩. ⟨hal-03591319⟩